Amylyx Drug Patent Portfolio
Amylyx owns 1 orange book drug protected by 5 US patents Given below is the list of Amylyx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583542 | Compositions of bile acids and phenylbutyrate compounds | 27 Jul, 2040 | Active |
| US10251896 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US10857162 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US11071742 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
| US9872865 | Compositions for improving cell viability and methods of use thereof | 24 Dec, 2033 | Active |
Latest Legal Activities on Amylyx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amylyx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9872865 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10857162 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10251896 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US9872865 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US11071742 |
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US10857162 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10857162 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US11071742 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10251896 |
| Letter re PTE application to FDA or Dept of Agriculture | 30 Sep, 2023 | US9872865 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10251896 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9872865 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10857162 |
Amylyx Drug Patents' Oppositions Filed in EPO
Amylyx drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 11, 2021, by Bruschettini S.R.L.. This opposition was filed on patent number EP14775675A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14775675A | Jan, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Opposition rejected |
| EP14775675A | Jan, 2021 | Bruschettini S.r.l. | Opposition rejected |
Amylyx's Family Patents
Amylyx Drug List
Given below is the complete list of Amylyx's drugs and the patents protecting them.
1. Relyvrio
Relyvrio is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11583542 | Compositions of bile acids and phenylbutyrate compounds |
27 Jul, 2040
(15 years from now)
| Active |
| US10251896 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(9 years from now)
| Active |
| US10857162 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(9 years from now)
| Active |
| US11071742 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(9 years from now)
| Active |
| US9872865 | Compositions for improving cell viability and methods of use thereof |
24 Dec, 2033
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relyvrio's drug page